-
17:55
-18:02
Cross-resistance between prior topoisomerase I inhibitor exposure and trastuzumab deruxtecan in recurrent gynecologic cancers
-
18:02
-18:09
Proteomics-based discovery and validation of TINAGL1 and BLVRB as predictive biomarkers for primary platinum resistance in ovarian cancer
-
18:09
-18:16
Decoding tumour burden and genomic alterations through cfDNA in epithelial ovarian cancer
-
18:16
-18:23
Sequential cisplatin–navitoclax therapy exploits an evolutionary vulnerability to delay recurrence in epithelial ovarian cancer
-
18:23
-18:30
Impact of cisplatin dosage in HIPEC on survival outcomes in the treatment of advanced ovarian cancer
-
18:30
-18:37
Analysis of the efficacy and safety of arsenic trioxide-based sequential combined chemotherapy in the treatment of recurrent and drug-resistant uterine malignancies: a real-world study
-
18:37
-18:44
Spatial transcriptomic dissection of cervical adenocarcinoma identifies immune-stromal niches and candidate biomarkers
-
18:44
-18:51
A shortcut from ovarian cancer development to metastasis: MYC/FASN/SEMA7A, a promising theragnostic axis

